Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
January 23, 2024 17:45 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
November 28, 2023 08:00 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
November 22, 2023 08:00 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 13, 2023 08:00 ET
|
Sagimet Biosciences Inc.
On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024 Two abstracts, including late-breaker, accepted at the American...
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
November 10, 2023 08:30 ET
|
Sagimet Biosciences Inc.
Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...